Advertisement

European Journal of Clinical Microbiology

, Volume 5, Issue 2, pp 193–196 | Cite as

Single and multiple dose pharmacokinetics of ciprofloxacin

  • U. Ullmann
  • W. Giebel
  • A. Dalhoff
  • P. Koeppe
Articles Ciprofloxacin: Pharmacokinetics

Abstract

Penetration of ciprofloxacin into nasal secretion was studied in 20 healthy volunteers to whom 500 mg oral ciprofloxacin was administered twice daily for eight days. Nasal secretion and blood samples were collected following the 1st and 15th dose and samples assayed microbiologically. Absolute concentrations of ciprofloxacin in serum and nasal secretion as well as kinetic parameters indicate that repeated administration did not result in significantly increased serum or nasal secretions levels although there was a tendency towards slight drug accumulation. The rate of penetration of ciprofloxacin into nasal secretion was 73% following the first oral dose and 90% following the 1 5th oral dose.

Keywords

Internal Medicine Blood Sample Healthy Volunteer Kinetic Parameter Oral Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Höfften, G., Lode, H., Prinzing, C., Borner, K., Koeppe, P.: Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy 1985, 27: 375–379.PubMedGoogle Scholar
  2. 2.
    Wingender, W., Graefe, K. H., Gau, W., Förster, D., Beermann, D., Schacht, R.: Pharmacokinetics of ciproflocaxin after oral and intravenous administration in healthy volunteers. European Journal of Clinical Microbiology 1984, 3: 355–359.CrossRefPubMedGoogle Scholar
  3. 3.
    Wise, R., Lockley, R. M., Webberly, M., Dent, J.: Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrobial Agents and Chemotherapy 1984, 26: 208–210.PubMedGoogle Scholar
  4. 4.
    Brumfitt, W., Franklin, I., Grady, D., Hamilton-Miller, J. M. T., Iliffe, A.: Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrobial Agents and Chemotherapy 1984, 26: 757–761.PubMedGoogle Scholar
  5. 5.
    Gonzales, M. A., Uribe, F., Moisen, S. D., Pichardo, F., Selen, A., Welling, P. G., Painter, B.: Multiple dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrobial Agents and Chemotherapy 1984, 26: 741–744.PubMedGoogle Scholar
  6. 6.
    Höffler, D., Dalhoff, A., Gau, W., Beermann, D., Michl, A.: Dose- and sex-independent disposition of ciprofloxacin. European Journal of Clinical Microbiology 1984, 3: 363–366.CrossRefPubMedGoogle Scholar
  7. 7.
    Ledergerber, B., Better, J. D., Joos, B., Flepp, M., Lüthy, R.: Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1985, 27: 350–352.PubMedGoogle Scholar
  8. 8.
    Crump, B., Wise, R., Dent, J.: Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1983, 24: 784–786.PubMedGoogle Scholar
  9. 9.
    Giebel, W., Schönleber, K. H., Breuninger, H., Ullmann, U.: Quantitative Bestimmung von Protein, Albumin und Antibiotika im Nasensekret gesunder Probanden. Archives of Oto-Rhino-Laryngology 1979, 225: 149–159.CrossRefPubMedGoogle Scholar
  10. 10.
    Ritschel, W. A.: Handbook of basic pharmacokinetics. Drug Intelligence Publications, Hamilton/IL, 1980.Google Scholar
  11. 11.
    Bergone-Berezin, E., Berthelot, G., Even, P., Dennewald, G., Stern, M.: Penetration of ciprofloxacin into respiratory secretions. European Journal of Clinical Microbiology 1985, 5: 197–200.Google Scholar
  12. 12.
    Shah, P. M., Strehl, R., Posselt, H. G., Bender, S. W.: Ciprofloxacin bei Mukoviszidose — zystische Fibrose, eine pharmakokinetische Untersuchung. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie 1984, 3: 685–690.Google Scholar
  13. 13.
    Boerema, J. B. J., Debruyne, F. M. J., Dalhoff, A.: Intraprostatic concentrations of ciprofloxacin after intravenous administration. Lancet 1984, ii: 695–696.CrossRefGoogle Scholar
  14. 14.
    Boerema, J. B. J., Dalhoff, A., Debruyne, F. M. J.: Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985, 31: 13–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoogkamp-Korstanje, J. A. A., van Oort, H. V., Schipper, J. J., van der Wal, T.: Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens. Journal of Antimicrobial Chemotherapy 1984, 14: 641–645.PubMedGoogle Scholar
  16. 16.
    Falser, N., Dalhoff, A., Weuta, H.: Ciprofloxacin concentrations in tonsils following a single intravenous infusion. Infection 1984, 12: 355–357.CrossRefPubMedGoogle Scholar
  17. 17.
    Schalkhäuser, K., Adam, D.: Diffusion von Ciprofloxacin in das Prostatagewebe. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie 1984, 3: 679–684.Google Scholar
  18. 18.
    Aronoff, G. E., Kenner, C. H., Sloan, R. S., Pottratz, S. T.: Multiple-dose ciprofloxacin kinetics in normal subjects. Clinical Pharmacology and Therapeutics 1984, 36: 384–388.PubMedCrossRefGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn 1986

Authors and Affiliations

  • U. Ullmann
    • 1
  • W. Giebel
    • 2
  • A. Dalhoff
    • 3
  • P. Koeppe
    • 4
  1. 1.Department of Medical MicrobiologyUniversity of KielKiel 1FRG
  2. 2.Biochemical Laboratory, ENT-ClinicUniversity of TübingenTübingen 1FRG
  3. 3.Pharma Research Center, Bayer AGWuppertal 1FRG
  4. 4.Medical Department, Klinikum SteglitzFree University of BerlinBerlin 45FRG

Personalised recommendations